The objective of the TG is to develop dose coefficients for radiopharmaceuticals administered to patients in diagnostic nuclear medicine.
The main work of the TG is to update Publication 128 (2015) by values calculated using new ICRP adult and paediatric reference voxel phantoms, Publication 107 nuclear decay data and Publication 103 dosimetry methodology as well as to develop biokinetic models for new substances and to identify substances contained in Publication 128 where model improvements are needed. As far as reasonable, a harmonisation of dosimetric and biokinetic models with those developed by TG 95 (IDC) for the ICRP OIR and EIR documents is intended.
For the calculation of dose coefficients for patients, a computer code IDAC 2.0 is being developed. The new dosimetric and biokinetic models will be implemented into this code, and a quality assurance procedure with the BfS code DOSAGE which is also used for QA in the IDC TG will be organised.
Augusto Giussani (Chair), Federal Office for Radiation Protection (BfS), Germany | ||
Sören Mattsson (Honourary Co-Chair), Skåne University Hospital Malmö and Lund University, Sweden | ||
Martin Andersson (Secretary), Lund University, SWEDEN | ||
Wesley E. Bolch (Member), University of Florida, USA | ||
Makoto Hosono (Member), Kindai University, Japan | ||
Alexandra Kamp (Member), Federal Office for Radiation Protection (BfS), Germany | ||
Keon Kang (Member), Seoul National University, Korea | ||
Sigrid Leide-Svegborn (Member), Skane University Hospital Malmö, Sweden | ||
Dietmar Nosske (Member), Germany | ||
Juan Camilo Ocampo Ramos (Member), Memorial Sloan Kettering Cancer Center, USA | ||
Nina Petoussi-Henss (Member), Helmholtz Zentrum München, Germany | ||
Katrine Riklund (Member), Umeå, SWEDEN | ||
Marie Sydoff (Member), Skane University Hospital, Lund, Sweden | ||
Lars Söderberg (Member), Skåne University Hospital, Sweden |